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W
e read with interest the article by
Polonsky et al. (1) reporting that
self-monitoring of blood glucose
(SMBG) improves glycemic control in
noninsulin-treated type 2 diabetes. In
the U.K., SMBG is recommended for
insulin-treated diabetes (2), and contro-
versy exists in relation to treatment with
lifestyle advice or oral hypoglycemic
agents (OHAs). A Cochrane review con-
cluded that there is insufﬁcient evidence
to support the use of SMBG in noninsulin-
treated type 2 diabetes (3). Furthermore, a
health technology assessment review sug-
gests that SMBG has limited clinical effec-
tiveness in improving glycemic control in
noninsulin-treated type 2 diabetes (4). In
view of the widespread use of SMBG, cost
implications, and the fact that U.K. man-
agement algorithms are based on HbA1c
targets (2), clarity is required on the role
of SMBG.
We used the SAIL (Secure Anony-
mised Information Linkage) databank (5)
to examine glucose strip prescribing in
relation to HbA1c in groups treated with
diet, OHAs, and insulin. SAIL contains
patientdatafrom35primarycaresystems
for the Swansea area (n 5 250,086). We
examined the diabetes population aged
18–7 0y e a r sw i t ha nH b A 1c performed
between January 2006 and January 2008
(n 5 6,223) who were prescribed testing
strips within the previous 6 months (n 5
1,674 with 4,608 prescriptions). The
number of glucose strips issued per pa-
tient in the past 6 months were grouped
by diabetes therapy (insulin, OHAs, diet)
and HbA1c (,6%, 6.0–7.9%, 8.0–9.9%,
$10.0%). Median and interquartile
ranges are described.
Weobservedthatstripprescribingfor
the diet and OHAs groups was similar,
and as expected, insulin was associated
with greater prescribing. Of the 1,674
patients, 25% (414) were treated with
insulin, 58% (970) with oral agents, and
17%(286)withdietalone.Fortheinsulin
group, there was a reverse association
between the HbA1c group (,6%, 6.0–
7.9%, 8.0–9.9%, $10.0%) and strip use
(300 [50–350], 250 [100–400], 200
[100–400], 100 [51–204]), P 5 0.01. In
the OHAs group, the respective values
were 50 (50–150), 100 (50–100), 100
(50–200), 100 (50–177), P , 0.01. No
clear pattern was seen in the diet group.
In those treated with insulin, better
HbA1c was associated with greater strip
prescribing. Conversely, for those treated
with OHAs, greater strip prescribing was
associated with a worse HbA1c. There are
limitations in our study that need to be
highlighted.Firstly,thisisanobservational
study; however, it is reﬂective of current
localpractice.Secondly,weexaminedstrip
prescribing over a 6-month period, and
this does not equate to actual SMBG. Nev-
ertheless, our study in routine clinical care
is in line with previous prospective studies
and clinical trials (3,4) and different to that
described by Polonsky et al. (1).
JEFFREY W. STEPHENS, FRCP
1
JULIE E. CARMAN, MBBCH
1
CAROLINE J. BROOKS, BSC
2
RONAN A. LYONS, MD
2
DAVID V. FORD, MBA
2
DAVID E. PRICE, FRCP
3
STEPHEN C. BAIN, FRCP
1
From the
1Institute of Life Sciences, Swansea Uni-
versity, Swansea, U.K.; the
2Health Information
Research Unit, Swansea University, Swansea,
U.K.; and the
3Department of Diabetes and
Endocrinology, Abertawe Bro Morgannwg Uni-
versity Health Board, Swansea, U.K.
Corresponding author: Jeffrey W. Stephens, j.w.
stephens@swansea.ac.uk.
DOI: 10.2337/dc11-0258
© 2011 by the American Diabetes Association.
Readers may use this article as long as the work is
properly cited, the use is educational and not for
proﬁt, and the work is not altered. See http://
creativecommons.org/licenses/by-nc-nd/3.0/ for
details.
Acknowledgments—Nopotentialconﬂictsof
interest relevant to this article were reported.
J.W.S. researched data, contributed to dis-
cussion, wrote the manuscript, and reviewed
and edited the manuscript. J.E.C. contributed
to discussion and wrote themanuscript. C.J.B.
researched data. R.A.L. researched data and
review and edited the manuscript. D.V.F.
researched data and reviewed and edited the
manuscript. D.E.P. reviewed and edited the
manuscript and contributed to discussion.
S.C.B. contributed to discussion and reviewed
and edited the manuscript.
Parts of this study were presented in poster
form at the Annual Professional Conference of
Diabetes UK, Liverpool, England, 3–5M a r c h
2010.
cccccccccccccccccccccccc
References
1. Polonsky WH, Fisher L, Schikman CH,
et al. Structured self-monitoring of blood
glucose signiﬁcantly reduces A1C levels in
poorly controlled, noninsulin-treated type
2 diabetes: results from the Structured
Testing Program study. Diabetes Care
2011;34:262–267
2. National Institute for Health and Clinical
Excellence. Type 2 diabetes: the manage-
ment of type 2 diabetes (update) [Internet],
2010. Available from http://guidance.nice.
org.uk/CG66. Accessed 5 April 2011
3. Welschen LM, Bloemendal E, Nijpels G,
et al. Self-monitoring of blood glucose in
patients with type 2 diabetes who are not
using insulin. Cochrane Database Syst Rev
2005:CD005060
4. Clar C, Barnard K, Cummins E, Royle P,
Waugh N; Aberdeen Health Technology As-
sessment Group. Self-monitoring of blood
glucoseintype2diabetes:systematicreview.
Health Technol Assess 2010;14:1–140
5. Ford DV, Jones KH, Verplancke JP, et al.
The SAIL databank: building a national ar-
chitecture for e-health research and evalu-
ation (Abstract). BMC Health Serv Res
2009;9:157
care.diabetesjournals.org DIABETES CARE, VOLUME 34, MAY 2011 e1259
ONLINE LETTERS